Prazopanib significantly prolongates progression-free survival in ovarian cancer patients?

2022-06-01 0 By

Ovarian cancer is as troubling to women as prostate cancer is to men as it is to women throughout life.For many years, the prevention and treatment of ovarian cancer has also been in full swing, the targeted drug prazopanib is one of the achievements.Prazopanib is an oral multikinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and stem cell factors. Preclinical and clinical studies support VEGFR and PDGFR as therapeutic targets for advanced ovarian cancer.An article published in the Journal of Clinical Oncology evaluated the efficacy of prazopanib maintenance therapy in patients with ovarian cancer whose disease did not progress during first-line chemotherapy.A total of 940 patients with histologically confirmed ovarian, fallopian tube, or peritoneal cancer who did not progress after their first surgery and at least five cycles of platinum-paclitaxel chemotherapy were enrolled in the trial.All patients were randomly assigned 1:1 to receive prazopanil 800mg daily or placebo for 24 months.The primary end point was progression-free survival as assessed by the investigator on RECIST1.0.Results: Prazopanib = maintenance significantly extended progression-free survival compared with placebo.Prazopanib maintenance therapy improved median progression-free survival by 5.6 months (HR, 0.77) in patients with advanced ovarian cancer who did not progress with first-line chemotherapy.